Secukinumab

Introduction

Secukinumab is a monoclonal antibody used primarily to treat autoimmune conditions by targeting specific inflammatory pathways. It is used in the management of conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Uses

Secukinumab is indicated for:

Plaque Psoriasis: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Psoriatic Arthritis: Active psoriatic arthritis in adults, either alone or in combination with methotrexate.
Ankylosing Spondylitis: Active ankylosing spondylitis in adults.

It helps manage symptoms and improve quality of life by reducing inflammation and other disease-related effects.

Brand Name	Secukinumab
Type
Weight
Generic	Secukinumab
Manufacturer
Available in	English বাংলা

Mechanism of Action

Secukinumab works by selectively inhibiting interleukin-17A (IL-17A), a cytokine involved in inflammatory and autoimmune responses. By binding to IL-17A, secukinumab prevents it from interacting with its receptor, thereby reducing inflammation and the associated symptoms of autoimmune diseases.

How Long Does It Take to Work?

The onset of action can vary depending on the condition being treated:

Plaque Psoriasis: Significant improvement is often seen within 1-2 weeks, with maximum effect typically observed within 12 weeks.
Psoriatic Arthritis and Ankylosing Spondylitis: Improvement in symptoms can be seen within 2-4 weeks, with the full therapeutic effect usually reaching its peak by 12 weeks.

Response times may vary based on individual patient factors and disease severity.

Absorption

Secukinumab is administered via subcutaneous injection. The absorption rate is approximately 80-90%, and peak plasma concentrations are usually achieved within 1-6 days after injection. The drug's absorption is not significantly affected by food or other factors.

Route of Elimination

Secukinumab is primarily eliminated via the reticuloendothelial system. It is metabolized through normal protein catabolism processes, with no specific organs or pathways involved in its clearance. It is not significantly excreted through the urine or feces.

Dosage

Plaque Psoriasis-

1. Recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable.

Psoriatic Arthritis-

1. For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosage and administration for plaque psoriasis.

2. For other psoriatic arthritis patients administer with or without a loading dosage. The recommended dosage:

With a loading dosage is 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
Without a loading dosage is 150 mg every 4 weeks
If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg.

Ankylosing Spondylitis-

1. Administer with or without a loading dosage. The recommended dosage:

With a loading dosage is 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
Without a loading dosage is 150 mg every 4 weeks

Typical dosing schedules are:

Plaque Psoriasis: Initial dose of 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Psoriatic Arthritis and Ankylosing Spondylitis: Initial dose of 150 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.

Dosage adjustments may be made based on individual response and tolerability.

Administration

Secukinumab is administered via subcutaneous injection. It can be given in the abdomen or thigh. The injection site should be rotated to reduce the risk of local reactions. Patients are typically trained on proper injection techniques if self-administering.

Side Effects

Common side effects include:

Upper respiratory infections, such as sinusitis and pharyngitis.
Headache, diarrhea, and nausea.
Injection site reactions, including pain and redness.

Serious side effects may include allergic reactions, increased risk of infections, and inflammatory bowel disease. Patients should report any severe or persistent symptoms to their healthcare provider.

Toxicity

There is no known specific antidote for secukinumab overdose. In case of suspected overdose, patients should be monitored for increased side effects and managed symptomatically. Severe allergic reactions may require immediate medical intervention.

Precautions

Precautions include:

Monitor for signs of infections and report any new symptoms to a healthcare provider.
Screen for and manage any pre-existing conditions that may be exacerbated by secukinumab.
Use with caution in patients with a history of chronic or recurrent infections.

Regular monitoring and medical consultations are recommended to ensure safety and efficacy.

Interaction

Secukinumab is not known to have significant drug interactions. However, it is important to inform the healthcare provider of all medications being taken, including over-the-counter drugs and supplements, to ensure comprehensive management and avoid potential interactions.

Disease Interaction

Secukinumab should be used with caution in patients with:

Active infections or a history of chronic infections.
Inflammatory bowel disease or other conditions that may be aggravated by immunosuppressive therapies.

Regular monitoring is advised for these patients to manage any potential exacerbations or complications.

Drug Interaction

Secukinumab does not have significant drug interactions. However, it is important to monitor for any adverse effects when used with other immunosuppressive agents or treatments for autoimmune conditions.

Food Interactions

Secukinumab can be administered with or without food, as food does not significantly impact its absorption or effectiveness.

Pregnancy Use

The safety of secukinumab during pregnancy is not well established. It is generally recommended to avoid use during pregnancy unless clearly needed. Discuss with a healthcare provider the potential risks and benefits if pregnancy is planned or occurs during treatment.

Lactation Use

The safety of secukinumab during lactation is not fully established. It is recommended to consult with a healthcare provider before using secukinumab while breastfeeding to evaluate the potential risks and benefits for the infant.

Acute Overdose

In case of an acute overdose, monitor the patient for increased side effects and manage symptomatically. There is no specific antidote for secukinumab, so supportive care is the primary approach.

Contraindication

Secukinumab is contraindicated in:

Patients with known hypersensitivity to secukinumab or any of its components.
Patients with active infections or serious infections that cannot be controlled.

Ensure no contraindications before initiating therapy.

Use Direction

Follow the prescribed dosing schedule and administration instructions. Proper technique for subcutaneous injection should be followed to minimize the risk of injection site reactions. Regular follow-ups with a healthcare provider are recommended to monitor treatment response and manage any adverse effects.

Storage Conditions

Store secukinumab in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the medication in its original carton to protect it from light. Dispose of any unused or expired medication properly according to local regulations.

Volume of Distribution

The volume of distribution for secukinumab is approximately 6-10 liters. This indicates a moderate distribution throughout the body’s tissues and fluids.

Half Life

The terminal half-life of secukinumab is approximately 27 days. This long half-life supports its dosing schedule and provides extended therapeutic effects with fewer administrations.

Clearance

Secukinumab is cleared primarily through the reticuloendothelial system. The systemic clearance is approximately 0.11 L/day/kg. This clearance rate ensures that the medication is effectively removed from the system while maintaining therapeutic levels.

See in details version Secukinumab also Secukinumab in bangla